The Pituitary Society Presents the

NINTH INTERNATIONAL

PITUITARY CONGRESS

June 7-9, 2005

Loews Coronado Bay Resort • San Diego, California

FINAL PROGRAM

Supported by Genentech and Ipsen through unrestricted educational grants
Officers & Board of Directors

President 2004 – 2005
David L. Kleinberg, New York, NY, USA

President Elect 2005-2006
Anne Klibanski, Boston, MA, USA

Executive Director
Mary Lee Vance, Charlottesville, VA, USA

Secretary-Treasurer
David L. Kleinberg, New York, NY, USA

Board of Directors
Felipe F. Casanueva, Santiago de Compostela, Spain
David R. Clemmons, Chapel Hill, NC, USA
Annamaria Colao, Naples, Italy
Lawrence A. Frohman, Chicago, IL, USA
David L. Kleinberg, New York, NY, USA
Anne Klibanski, Boston, MA, USA
Steven W. J. Lamberts, (ex-officio), Rotterdam, The Netherlands
Shlomo Melmed, Los Angeles, CA, USA
Agnes Schonbrunn, Houston, TX, USA
Paul M. Stewart, Birmingham, UK
Brooke Swearingen, Boston, MA, USA
Mary Lee Vance, Charlottesville, VA, USA
John Wass, Oxford, UK

Committee Chairpersons
Clinical Initiatives Andrea Giustina, Brescia, Italy
Communications Lawrence A. Frohman, Chicago, IL, USA
Development David L. Kleinberg, New York, NY, USA
Membership Laurence Katznelson, Boston, MA, USA
Meetings Anne Klibanski, Boston, MA, USA
Nominations Shlomo Melmed, Los Angeles, CA, USA
John Wass, Oxford, UK

Pituitary: The Official Journal of the Pituitary Society
Editorial Office
Kluwer Academic Publishers
101 Philip Drive
Assinippi Park
Norwell, MA 02061
USA
Dear Colleague,

Following a long-standing tradition, the Pituitary Society has organized the 9th International Pituitary Congress. This Congress will offer the opportunity for worldwide experts and fellows in training to gather in a quiet atmosphere in order to consider in-depth new findings and problems related to pituitary disorders. We are pleased that you will be joining us for a free exchange of ideas.

We on the Program Committee have selected a group of speakers of international stature that are currently addressing the most relevant basic and clinical problems in the pituitary physiology and disease. A new formula for the Hot Topics session, as well as a session on New Technological Advances, has been included. In addition, we will develop a set of Guidelines for Diagnosis and Management of Prolactinomas. We are sure you will enjoy this exciting Program.

Finally, we join with the officers and meeting organizers to thank Genentech and Ipsen for the unrestricted educational grants that will help support and make this meeting possible.

Welcome again to two days of excellent science and companionship.

Felipe Casanueva, (Spain)

Vivien Bonert, (USA)

David Clemmons, (USA)

Ken Ho, (Australia)

Paul Kelly, (France)
Symposia Schedule

Tuesday, June 7, 2005

5:30 pm – 7:30 pm

SESSION ONE

ENDOCRINE AND METABOLIC ACTIONS OF GHRELIN
Constellation Ballroom (2nd Floor)
Chairpersons:
Ariel Barkan (Ann Arbor, MI, USA)
Aart van der Lely (Rotterdam, Netherlands)

The Basic Physiology of Ghrelin - More Than Just a GH Secretagogue
Marta Korbonits (London, UK)

Novel Agonist and Antagonist Analogs of Ghrelin
Michael Culler (Milford, MA, USA)

Neuroendocrine and Peripheral Actions of Ghrelin
Ezio Ghigo (Turin, Italy)

Ghrelin as a Tool to Understanding Diabesity
Matthias Tschop (Cincinnati, OH, USA)

7:30 pm - 8:15 pm
Chairpersons:
Steven Lamberts (Rotterdam, Netherlands)
Alan Robinson (Los Angeles, CA, USA)

The Contribution of IGF-I to the Regulation of Somatotropic Axis and Metabolism
Derek LeRoith (Bethesda, MD, USA)

7:30 pm – 8:30 pm
Continental Breakfast
Commodore Ballroom Foyer (1st Floor)

8:30 am – 10:30 am

SESSION TWO

PITUITARY FACTORS REGULATING AND DISRUPTING ENDOCRINE FUNCTIONS
Commodore Ballroom (1st Floor)
Chairpersons:
Günter Stalla (Munich, Germany)
Wylie Vale (La Jolla, CA, USA)

Adenohypophysis Formation in Zebrafish
Matthias Hammerschmidt (Freiburg, Germany)

Pituitary Cell Differentiation
Jacques Drouin (Montreal, Quebec, Canada)

Mechanisms and Biomarkers of Endocrine Disruption at the Hypothalamo-pituitary Unit
Manuel Tena (Cordoba, Spain)

GPR54, KIS 1, and GnRH Function
Nicholas De Roux (Paris, France)

10:30 am – 11:30 am
Poster Viewing and Coffee Break
2nd Floor

Wednesday, June 8, 2005

7:30 am – 8:30 am
Continental Breakfast
Commodore Ballroom Foyer (1st Floor)

8:30 am

The Contribution of IGF-I to the Regulation of Somatotropic Axis and Metabolism
Derek LeRoith (Bethesda, MD, USA)
11:30 am – 2:30 pm

CONCURRENT SESSIONS (lunch provided)

▲ Guidelines for the Diagnosis and Management of Prolactinomas
Commodore Ballroom
Chairpersons:
Felipe Casanueva (Santiago de Compostela, Spain)
Andrea Giustina (Brescia, Italy)

Short Presentations:
Janet Schlechte (Iowa City, IA, USA)
Paul Kelly (Paris, France)
Roger Abs (Antwerp, Belgium)
John Wass (Oxford, UK)
Rudolf Fahlbusch (Erlangen, Germany)
David Kleinberg (New York, NY, USA)
Mark Molitch (Chicago, IL, USA)
Annamaria Colao (Milan, Italy)

Break out groups for discussion
Group 1 - Commodore Ballroom
Laura De Marinis (Rome, Italy)
Monica Gadelha (Rio de Janeiro, Brazil)

Group 2 - Constellation A (2nd Floor)
Eleni Dimaraki (Evanston, IL, USA)
Sonia Gaztambide (Barakaldo, Spain)

Group 3 - Constellation B (2nd Floor)
Yona Greenman (Tel Aviv, Israel)
Fahretin Kelestimur (Kayseri, Turkey)

OR

▲ New Technological Advances:
Britannia/Cambria (2nd Floor)
Chairpersons:
Rolf Gaillard (Lausanne, Switzerland)
Agnes Schonbrunn (Houston, TX, USA)

• Use and Interpretation of Gene Chip/RNA Expression Microarray Data
Lisa White (Houston, TX, USA)

• Exploring Brain Circuitry with Viral Transneuronal Tracing: Applications, Limitations and New Opportunities
J. Patrick Card (Pittsburgh, PA, USA)

2:30 pm – 4:30 pm

SESSION THREE

PITUITARY TARGETS AND TUMORS
Commodore Ballroom (1st Floor)
Chairpersons:
Laurence Katznelson (Stanford, CA, USA)
Susan Webb (Barcelona, Spain)

The Molecular Basis for Growth Hormone Action in Growth
Michael Waters (St. Lucia, Australia)

Transgenic Models for Pituitary Tumors
Ines Donangelo (Los Angeles, CA, USA)

Are Pituitary Tumors More Common Than Previously Thought?
Albert Beckers (Liege, Belgium)

Advances in Treatment of Cushing’s Disease
Francesco Cavagnini (Milan, Italy)

4:30 pm – 5:00 pm
Poster Viewing and Coffee Break
2nd Floor

5:00 pm – 7:00 pm

SESSION FOUR

THE EXPANDING ROLES OF THE IGF-I COMPLEX
Commodore Ballroom (1st Floor)
Chairpersons:
Francesco Minuto (Milan, Italy)
Christian Strasburger (Berlin, Germany)

Measurement and Standardization of IGF-I Complex Measurement
Georg Brabant (Hanover, Germany)

The GH/IGF-1 Response to Exercise and Exercise Training. Effect of Age, Regional Distribution of Fat and Sex Steroids
Arthur Weltman (Charlottesville, VA, USA)

(continued on next page)
SESSION FOUR  (Continued)

New Aspects on the Use of IGF-I as Treatment
David Clemmons (Chapel Hill, NC, USA)

IGF-I and the Eye
Fatima Bosch (Barcelona, Spain)

7:30 pm
Cocktail Reception
Commodore Ballroom (1st Floor)

8:30 pm
Gala Dinner Celebrating the 20th Anniversary of Recombinant GH Therapy
Commodore Ballroom (1st Floor)

Thursday, June 9, 2005

7:30 am – 8:30 am
Continental Breakfast
Commodore Ballroom Foyer (1st Floor)

8:30 am – 9:30 am
Presentation of the Prolactinoma Guidelines Draft
Commodore Ballroom (1st Floor)
Felipe Casanueva (Santiago de Compostela, Spain)
Andrea Giustina (Brescia, Italy)

9:30 am - 11:00 am
Hot Topics
Commodore Ballroom (1st Floor)
Chairpersons:
Paolo Beck-Peccoz (Milan, Italy)
Lawrence Frohman (Chicago, IL, USA)

Somatostatin Analogues Stimulate p27 and Inhibit Mitogen-activated Protein Kinase (MAPK) in Human Pituitary Tumours
Marta Korbonits (London, UK)

Identification of Novel Candidates for Pituitary Tumorigenesis
Lynette Cary (Aurora, CO, USA)

Epithelial Growth Factor Receptor (EGF-R) Activation Induces Pituitary Tumor Transforming Gene (PTTG) Expression in Murine Pituitary Folliculostellate TtT/GF
George Vlotides (Los Angeles, CA, USA)

Estrogen and Selective ER Modulators Regulate GH Signaling Through Distinct Mechanisms
Kin-chuen Leung (Sydney, NSW, Australia)

Down-regulation of PRKAR1A Gene in the Development of Pituitary Adenomas in the GHRH Over-expressing Mice
Dalia Batista (Bethesda, MD, USA)

11:00 am - 11:45 am
Commodore Ballroom (1st Floor)
Chairpersons:
Beverly Biller (Boston, MA, USA)
Phillipe Jaquet (Marseille, France)

Neuroendocrine Function and Metabolism During Sleep and During Sleep Deprivation
Eve Van Cauter (Chicago, IL, USA)

12:00 Noon
Adjourn

Hypermethylation and Reduced Expression of SOCS-1 in Pituitary Adenomas
Rolf Buslei (Erlangen, Germany)
### Cushing’s Syndrome and the Corticotrope Axis  
**LOCATION: Aurora**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Heald, AF</td>
<td>Comparison of Quality of Life in Patients with Treated Pituitary Cushing's and Nelson's Syndrome vs. Adrenal Cushing's</td>
</tr>
<tr>
<td>2</td>
<td>Suzuki, M</td>
<td>ACTH and Alpha Subunit (SU) Co-expression in the Same Human Pituitary Corticotroph Cell Adenomas: Rare Trans-cell Lineage Functional Differentiation</td>
</tr>
<tr>
<td>3</td>
<td>Rollin, GAFS</td>
<td>Transsphenoid Pituitary Surgery in Cushing’s Disease</td>
</tr>
<tr>
<td>4</td>
<td>Suzuki, M</td>
<td>A Case of Cushing’s Disease Caused by Pituitary Double Adenomas with Concomitant GH and ACTH Product</td>
</tr>
<tr>
<td>5</td>
<td>Heald, AH</td>
<td>A Cross-sectional Study to Investigate Long-term Cognitive Function in People with Treated Pituitary Cushing’s Disease</td>
</tr>
<tr>
<td>6</td>
<td>De Marinis, L</td>
<td>Evaluation of GH Secretion after Long-term Remission of Cushing's Disease</td>
</tr>
<tr>
<td>7</td>
<td>van der Hoek, J</td>
<td>Somatostatin Analog Therapy in Cushing’s Disease?</td>
</tr>
<tr>
<td>8</td>
<td>Faggiano, A</td>
<td>Sulfur Amino Acid Unbalance in Cushing’s Disease: Insight in Homocysteine and Taurine Levels in Patients with Active and Cured Disease</td>
</tr>
<tr>
<td>9</td>
<td>Pivonello, R</td>
<td>Progressive Increase of Cardiovascular Risk in Patients Cured from Cushing’s Disease</td>
</tr>
<tr>
<td>10</td>
<td>Klose, M</td>
<td>Evaluation of the 250 Microgram ACTH Test - Is There a Need for Gender Specific Reference Ranges?</td>
</tr>
<tr>
<td>10a</td>
<td>Sobrinho, LG</td>
<td>Cyclic Cushing’s Followed-up for 12 years</td>
</tr>
<tr>
<td>11</td>
<td>Lindsay, JR</td>
<td>ACTH Measured by Immunoradiometric Assay (IRMA) Offers Similar Diagnostic Accuracy Compared with Radioimmunoassay (RIA) During the Differential Diagnosis of Cushing’s Syndrome</td>
</tr>
<tr>
<td>11a</td>
<td>Kennedy, L.</td>
<td>Circulating Adiponecinctin in ACTH-dependent Cushing’s Syndrome, Acromegaly, and Control Subjects</td>
</tr>
</tbody>
</table>

### Prolactinomas  
**LOCATION: Britannia/Cambria Foyer**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Mangupli, R</td>
<td>Prolactinomas in Children and Very Young Patients – Clinical Presentation and Long Term Therapy of 19 Cases</td>
</tr>
<tr>
<td>13</td>
<td>Minematsu, T</td>
<td>Prop-1 Overexpression and Prolactin-producing Pituitary Adenomas: Studies on Human Pituitary Adenomas with Real Time RT-PCR and Prop-1 Transgenic Mice</td>
</tr>
<tr>
<td>14</td>
<td>Oneto, A</td>
<td>Prolactin (PRL) Response to Thyrotropin – Releasing Hormone (TRH) in Patients with Macroprolactinemia</td>
</tr>
<tr>
<td>15</td>
<td>De Marinis, L</td>
<td>Long-Term Outcome of Neurosurgery vs. Dopamine Agonists in the Treatment of Microprolactinomas</td>
</tr>
<tr>
<td>16</td>
<td>Popii, V</td>
<td>Effects of Tamoxifen and Raloxifene on Prolactin Gene Expression and Secretion in GH4 Cells</td>
</tr>
<tr>
<td>17</td>
<td>Rangi, J</td>
<td>Mental Status Changes and Hypertension: Two Possible Fatal Side Effects of Cabergoline</td>
</tr>
</tbody>
</table>

### Acromegaly and the Somatotrope Axis  
**LOCATION: Constellation Foyer North**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Barnett, P</td>
<td>Treatment Outcomes in 76 Patients with Acromegaly 10 Years After Diagnosis</td>
</tr>
<tr>
<td>19</td>
<td>Liu, Q</td>
<td>Receptor Signaling and Endocytosis are Differentially Regulated by Somatostatin Analogs</td>
</tr>
<tr>
<td>20</td>
<td>Carreira, MC</td>
<td>Adenosine Does Not Bind to the Ghrelin Receptor (GHS-R1a) but Uses Part of Its Intracellular Route</td>
</tr>
<tr>
<td>21</td>
<td>Katakami, H</td>
<td>Suppression by Anesthesia of Plasma Intact Ghrelin Levels and GH</td>
</tr>
<tr>
<td>22</td>
<td>Gedik, VT</td>
<td>Predictive Role of Preoperatif IGF-1 on Operative Outcome of Patients with Acromegaly</td>
</tr>
<tr>
<td>23</td>
<td>Fahrbusch, R</td>
<td>Improving Results of Transsphenoidal Surgery in Acromegaly by Intraoperative Magnetic Resonance Imaging?</td>
</tr>
<tr>
<td>24</td>
<td>Katakami, H</td>
<td>Detection by a Novel and Ultrasensitive Enzyme Immunoassay of Pulsatile hGH Secretion in Spontaneous Dwarf Rats with Targeted Expression of hGH-transgene to the Pituitary</td>
</tr>
<tr>
<td>25</td>
<td>Unger, N</td>
<td>Somatostatin Receptor Analysis in Pituitary Adenomas</td>
</tr>
<tr>
<td>26</td>
<td>Cukiert, A</td>
<td>Effects of Octreotide-LAR Withdrawal in Acromegalic Patients Treated by Primary or Secondary Radiotherapy</td>
</tr>
<tr>
<td>27</td>
<td>Resmini, E</td>
<td>Dissociation Between Antiproliferative and Antisecretive Effects of Octreotide LAR in Acromegaly: In Vivo and In Vitro Study</td>
</tr>
<tr>
<td>28</td>
<td>Curto, L</td>
<td>Simultaneous Coexistence of GH-Secreting Pituitary Adenoma, Meningioma and Carotid Artery Aneurysm</td>
</tr>
<tr>
<td>29</td>
<td>Cukiert, A</td>
<td>Intrasellar Internal Carotid Aneurysm Coexisting with a GH-Secreting Pituitary Adenoma in an Acromegalic Patient</td>
</tr>
<tr>
<td>30</td>
<td>Petersenn, S</td>
<td>Primary Therapy of Acromegaly with Somatostatin Analogues–Analysis of the German Acromegaly Register</td>
</tr>
<tr>
<td>31</td>
<td>Zatelli, MC</td>
<td>Dopamine and Somatostatin Receptor Expression Influences SRIF Analogs Effects on Pituitary Adenomas In Vitro</td>
</tr>
<tr>
<td>32</td>
<td>Zatelli, MC</td>
<td>SRIF Receptor (SSTR) 1 and SSTR5 Agonists Differentially Affect GH-secreting Pituitary Adenomas</td>
</tr>
<tr>
<td>33</td>
<td>Mercado, M</td>
<td>A Prospective, Multicenter Study to Investigate the Efficacy, Safety and Tolerability of Sandostatin® LAR® in the Primary Therapy of Patients with Newly Diagnosed Acromegaly</td>
</tr>
</tbody>
</table>
Acromegaly and the Somatotrope Axis (con’t.)

**LOCATION:** Sovereign

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Nugaram, R</td>
<td>Acromegaly with Empty Sella</td>
</tr>
<tr>
<td>35</td>
<td>Secunza, N</td>
<td>High Morbi-mortality and Reduced Quality of Life in Acromegaly</td>
</tr>
<tr>
<td>36</td>
<td>Astruc, B</td>
<td>Octreotide LAR and Lanreotide Autogel Have Different Pharmacokinetic Profiles</td>
</tr>
<tr>
<td>37</td>
<td>Mantovani, G</td>
<td>CyclicAMP/PAK Signalling and Cell Proliferation in Non-secreting and GH-secreting Pituitary Adenomas</td>
</tr>
<tr>
<td>38</td>
<td>Learned-Miller, E</td>
<td>Early Diagnosis of Acromegaly by Facial Pattern Recognition</td>
</tr>
<tr>
<td>39</td>
<td>Schmid, HA</td>
<td>Regulation of Ghrelin Secretion by Somatostatin Analogues in Rats</td>
</tr>
<tr>
<td>40</td>
<td>Fainstein, DP</td>
<td>Acromegaly Due to Ectopic Production of GHRH by a Metastatic Carcinoid Tumor</td>
</tr>
<tr>
<td>41</td>
<td>Gadelha, MR</td>
<td>Medical Therapy of Acromegaly with an Octreotide Subdermal Implant</td>
</tr>
<tr>
<td>42</td>
<td>Fleseriu, M</td>
<td>Lack of Significant Immunostaining for Growth Hormone (GH) in Patients With Acromegaly</td>
</tr>
<tr>
<td>43</td>
<td>Bronstein, M</td>
<td>Brazilian Experience in the Treatment of 250 Acromegalic Patients with Sandostatin® LAR®</td>
</tr>
<tr>
<td>44</td>
<td>Gadelha, M</td>
<td>Observational Study for Evaluation of QoL of Acromegalic Patients in Use of Sandostatin LAR</td>
</tr>
<tr>
<td>45</td>
<td>Paisley, AN</td>
<td>Pegvisomant Interference in Growth Hormone (GH) Assays Results in Underestimation of GH Levels</td>
</tr>
<tr>
<td>46</td>
<td>Kim, SW</td>
<td>Acylated ghrelin secretion is suppressed during OGTT or ITT irrespective of basal GH secretion</td>
</tr>
<tr>
<td>47</td>
<td>Mercado, M</td>
<td>A Prospective, Multicenter Study to Investigate the Efficacy, Safety and Tolerability of Sandostatin® LAR® in the Primary Therapy of Patients with Newly Diagnosed Acromegaly</td>
</tr>
<tr>
<td>48</td>
<td>Caron, Ph</td>
<td>Pregnancy Outcome after Somatostatin analogue (SMSa) Treatment of Acromegalic Women</td>
</tr>
</tbody>
</table>

**Hypopituitarism**

**LOCATION:** Lenore

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>Dutta, P</td>
<td>Suprasellar Tuberculare Abscess Presenting as Panhypopituitarism</td>
</tr>
<tr>
<td>50</td>
<td>Di Somma, C</td>
<td>2-year GH Replacement in Young Adult Patients with GH Deficiency: Gender Difference in Bone Status</td>
</tr>
<tr>
<td>51</td>
<td>Burt, MG</td>
<td>Perturbation Of Whole Body Protein Methabolism In Cushing's Syndrome And Growth Hormone Deficiency</td>
</tr>
<tr>
<td>52</td>
<td>Shitamu, A</td>
<td>Isolated Adrenocorticotropic Hormone Deficiency Presenting with Recurrent Severe Hypercalcemia</td>
</tr>
<tr>
<td>53</td>
<td>Fatih, T</td>
<td>Evaluation of Pituitary Secretions in Survivors of Traumatic Brain Injury: A Prospective Study</td>
</tr>
<tr>
<td>54</td>
<td>Liu, JK</td>
<td>Clinical Significance of Sphenoid Sinus Mucosal Thickening in Pituitary Apoplexy</td>
</tr>
<tr>
<td>55</td>
<td>Sekhar, RV</td>
<td>Short- and Long-term Effects of Low Dose Growth Hormone (GH) Replacement on Glucose Metabolism in Growth Hormone Deficient (GHD) Adults</td>
</tr>
<tr>
<td>56</td>
<td>Dutta, P</td>
<td>Nontumoral Hypopituitarism of Childhood</td>
</tr>
<tr>
<td>57</td>
<td>Sathiavageswaran, M</td>
<td>Improvement of Cognitive Function in Elderly Growth Hormone Deficient Patients Treated with Growth Hormone: A Placebo-controlled 12-month Study</td>
</tr>
<tr>
<td>58</td>
<td>Dusick, JR</td>
<td>Acute Hormonal Changes after Traumatic Brain Injury</td>
</tr>
<tr>
<td>59</td>
<td>Kelly, DF</td>
<td>Neurobehavioral Impact of Growth Hormone Insufficiency after Moderate or Severe Traumatic Brain Injury</td>
</tr>
<tr>
<td>60</td>
<td>Dutta, P</td>
<td>Wegner's Granulomatosis Presenting as Diabetes Insipidus</td>
</tr>
<tr>
<td>61</td>
<td>Cukiert, A</td>
<td>Hyponatremia After Transsphenoidal Procedures for Pituitary Adenoma</td>
</tr>
</tbody>
</table>

**New Methodology – Epidemiology**

**LOCATION:** Constellation Foyer South

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>62</td>
<td>Daly, A</td>
<td>A Multicenter Collaborative Study to Measure the Prevalence of Pituitary Disease: Methodology and Preliminary Findings</td>
</tr>
<tr>
<td>63</td>
<td>Ferone, D</td>
<td>Rapid Visual Recovery with Hyperbaric Oxygen Therapy in Patient Presenting Delayed Radiation-induced Optic Neuropathy after Stereotactic Radiosurgery for Pituitary Adenoma</td>
</tr>
<tr>
<td>64</td>
<td>Bonneville, JF</td>
<td>3.0T MRI of the Pituitary Gland</td>
</tr>
<tr>
<td>65</td>
<td>Kriści, AF</td>
<td>Surgical Cures in Cavernous Sinus Secreting Pituitary Adenomas</td>
</tr>
<tr>
<td>66</td>
<td>Gnanalingham, KK</td>
<td>Quantitative Assessment of the Time Course of Recovery in Visual Field Following Transsphenoidal Surgery for Pituitary Adenomas: Predictive Factors for a Good Outcome</td>
</tr>
<tr>
<td>67</td>
<td>Revill, K</td>
<td>Characterization of the Ribosomal S6 Kinase Alpha 2 (RSK) Gene in Pituitary Tumours</td>
</tr>
<tr>
<td>68</td>
<td>Cruz-Soto, ME</td>
<td>PTTG is Required for Murine Pituitary Cell Cycle Progression</td>
</tr>
</tbody>
</table>

**Other Pathologies**

**LOCATION:** Aurora

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>69</td>
<td>Casagrande, A</td>
<td>Long Term Control of Hyperthyroidism with Octreotide-Lar 20 mg Treatment in a Pituitary TSH-Secreting Adenoma</td>
</tr>
<tr>
<td>70</td>
<td>Katz, D</td>
<td>Thyrotropin-Secreting Pituitary Adenoma Co-secretory Growth Hormone: Two Clinical Cases</td>
</tr>
<tr>
<td>71</td>
<td>Staldercker, G</td>
<td>Silent Plurihormonal TSH-Secreting Pituitary Macroadenoma. A Case Report</td>
</tr>
<tr>
<td>72</td>
<td>Chiang, E</td>
<td>Need for Periodic Pituitary Imaging in Patients with MEN I Syndrome</td>
</tr>
<tr>
<td>73</td>
<td>Heald, AH</td>
<td>Natural History of Non-Functioning Pituitary Adenomas Managed Conservatively at a Neuroscience Centre</td>
</tr>
<tr>
<td>74</td>
<td>Mattzoo, C</td>
<td>Endonasal Transsphenoidal Surgery for Residual Endocrine-inactive Pituitary Macroadenomas</td>
</tr>
<tr>
<td>75</td>
<td>Miranda, PAC</td>
<td>Involvement of Renin-angiotensin System in Hyperglycemic Response to Different Models of Stress</td>
</tr>
<tr>
<td>76</td>
<td>Surya, S</td>
<td>Cerebrohypophysealoma: Outcome and Quality of life – A Single Center Study</td>
</tr>
</tbody>
</table>
Cushing’s Syndrome and the Corticotrope Axis                      Aurora
Prolactin and the Prolactinomas                                Britannia/Cambria Foyer
Acromegaly and the Somatotrope Axis                           Constellation Foyer North/Sovereign
Hypopituitarism                                                 Lenore
New Methodology - Epidemiology                                 Constellation Foyer South
Other Pathologies                                               Aurora

Supported through unrestricted educational grants from

Genentech

and

IPSEN

Congress Secretariat

Ms. Bari Laner
Ninth International Pituitary Congress
8700 Beverly Blvd., Atrium 119
Los Angeles, CA  90048
UNITED STATES

Tel:    +310-423-2937
Fax:    +310-423-0309
Email:  secretariat@pituitarycongress2005.com
Web:    www.pituitarycongress2005.com